IL-31
IL-31 Informations sur la molécule
| Nom anglais | Interleukin-31 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 5 | Alias de la cible | Interleukin 31，IL-31 |
| Phase de R&D la plus avancée | Phase 2 Clinical | ||
| Nom anglais | Interleukin-31 |
| Alias de la cible | Interleukin 31，IL-31 |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 5 |
| Phase de R&D la plus avancée | Phase 2 Clinical |
IL-31 Liste de produits
- Attribut
Protein (8)Kits (1)
- Bibliothèque de produits
En ligne (9)
- Espèces
Human (4)Cynomolgus (3)Mouse (2)
- Étiquette
His Tag (4)His Tag & Avi Tag (3)Tag Free (1)- (1)
- Marqueur
Unconjugated (5)Biotin-labeled (3)- (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT IL1-H5219 |  Human | HEK293 | Human IL-31 Protein, premium grade (Mass Spec verified) |  |  |  |  Ajouter au panier |
| Human | HEK293 | Human IL-31 Protein, His Tag, low Endotoxin (MALS verified) |  | | | Ajouter au panier | |
HOT IL1-C5245 |  Cynomolgus | HEK293 | Cynomolgus IL-31 Protein, His Tag, low endotoxin |  | | | Ajouter au panier |
| Human | - | Human IL-31 ELISA Kit | Ajouter au panier | ||||
| Human | HEK293 | Biotinylated Human IL-31 Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier | |
 Mouse | HEK293 | Mouse IL-31 Protein, His Tag (HPLC verified) |  | | | Ajouter au panier | |
| Mouse | HEK293 | Biotinylated Mouse IL-31 Protein, His,Avitag™ (MALS & BLI verified) |  | |  | Ajouter au panier | |
| Cynomolgus | HEK293 | Cynomolgus IL-31 Protein, His Tag, ultra low endotoxin (MALS verified) |  | | | Ajouter au panier | |
| Cynomolgus | HEK293 | Biotinylated Cynomolgus IL-31 Protein, His,Avitag™ (HPLC verified) |  | | | Ajouter au panier |
Quantité totale9
- 1
IL-31Contexte de la molécule
IL-31 is an inflammatory cytokine that helps trigger cell-mediated immunity against pathogens. Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR. It has also been identified as a major player in a number of chronic inflammatory diseases, including atopic dermatitis. May function in skin immunity. IL-31 is produced by a variety of cells, namely type 2 helper (TH2) T-cells. IL-31 sends signals through a receptor complex made of IL-31RA and oncostatin M receptor β (OSMRβ) expressed in immune and epithelial cells. These signals activate three pathways: ERK1/2 MAP kinase, PI3K/AKT, and JAK1/2 signaling pathways.
IL-31Alias de la molécule
IL-31,IL31,Interleukin-31
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| JNJ-5939 | JNJ-5939; NM-26; NM26-2198; JNJ-95475939 | Phase 2 Clinical | Numab Therapeutics Ag | Dermatitis, Atopic; Inflammation | Details |
| ATTO-3712 | ATTO-3712 | Phase 1 Clinical | Attovia Therapeutics Inc | Dermatitis, Atopic; Pruritus | Details |
| BBT-001 | BBT001; BBT-001 | Phase 1 Clinical | Bambusa Therapeutics Inc | Dermatitis, Atopic | Details |
| ZL-1503 | ZL-1503 | Phase 1 Clinical | Zai Lab Ltd | Dermatitis, Atopic | Details |
| ATTO-1310 | ATTO-1310 | Phase 1 Clinical | Attovia Therapeutics Inc | Dermatitis, Atopic; Pruritus | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques